Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematological Malignancy & Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DDX41 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DDX41 Recombinant Protein (WT & R525H Mutant) High purity (>95%), Endotoxin Controlled. Sequence Verified. E. coli/Insect cell expressed. |
View DDX41 Products |
| Gene Delivery | DDX41 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View DDX41 Products |
| Benchmark Ab | Anti-DDX41 Antibody Recombinant positive control for Western Blot and IP. |
View DDX41 Products |
| Validator | DDX41 siRNA Set For knockdown verification in target validation assays. |
View DDX41 Products |
| Related Target A | STING (TMEM173) Downstream signaling mediator of DDX41-mediated cytosolic DNA sensing. |
View STING Products |
| Related Target B | cGAS Synergistic cytosolic DNA sensor cooperating in the innate immune response. |
View cGAS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ATPase & Helicase Activity Verification | Enzymatically active recombinant proteins verified by sequence integrity and high purity (>95%). |
| Mutation-specific Screening (R525H) | Both WT and clinically relevant mutant (R525H) proteins available for comparative screening. |
| Lack of Controls | Highly validated benchmark antibodies and siRNA sets included for functional assay baselines. |
| Off-target Helicase Screening | Homolog panel screening supported by high-purity DEAD-box family proteins. |
Live DDX41 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DDX41 therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapies to targeted small molecule modulators and synthetic lethality strategies. DDX41, an essential DEAD-box RNA helicase, is a critical germline and somatic mutation driver in late-onset Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). As first-generation therapies targeting the spliceosome and innate immune pathways reach the clinic, the next wave of R&D is targeting the specific catalytic and binding pockets of mutated DDX41 (such as the R525H hotspot) to exploit synthetic lethal vulnerabilities in hematological malignancies, as well as modulating its role as a cytosolic DNA sensor for cancer immunotherapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | MDS, AML (DDX41-mutant) | ATPase/Helicase activity assays (Need high-purity WT vs Mutant proteins) |
| STING Pathway Modulators | Pharmaceutical Corporates | Solid Tumors, Autoimmune Diseases | In vitro binding assays (Need sequence-verified DDX41 and STING proteins) |
| Gene Therapy / RNAi | Preclinical Stage Biotechs | Hematological Malignancies | In vitro knockdown validation (Need verified siRNA and Lentivirus systems) |